We are live on
!
Find out more
BG
Bellevue Group Portfolio holdings
AUM
$4.2B
1-Year Est. Return
54.85%
This Fund
S&P 500
This Quarter
Est. Return
+3.94%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.45B
AUM Growth
+$719M
(+8.2%)
Cap. Flow
+$643M
Cap. Flow
% of AUM
6.8%
Top 10 Holdings %
Top 10 Hldgs %
29.09%
Holding
237
New
15
Increased
96
Reduced
78
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACCD
Accolade Inc
ACCD
|
+$56.6M |
| 2 |
Revolution Medicines
RVMD
|
+$46M |
| 3 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
+$43.7M |
| 4 |
EPIX
ESSA Pharma
EPIX
|
+$42.4M |
| 5 |
Becton Dickinson
BDX
|
+$33.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$86.9M |
| 2 |
Halozyme
HALO
|
+$47.2M |
| 3 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
+$38.1M |
| 4 |
ESPR
Esperion Therapeutics
ESPR
|
+$33.9M |
| 5 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$33.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.93% |
| 2 | Industrials | 0.88% |
| 3 | Technology | 0.47% |
| 4 | Consumer Discretionary | 0.04% |
| 5 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GOCO
226
DELISTED
GoHealth
GOCO
| – | – |
-22,495
| Closed | -$4.61M |
|
227
Interactive Brokers
IBKR
$40.8B
| – | – |
-37,600
| Closed | -$573K |
|
228
Pfizer
PFE
$141B
| – | – |
-73,900
| Closed | -$2.72M |
|
229
Sociedad Química y Minera de Chile
SQM
$19.3B
| – | – |
-18,200
| Closed | -$893K |
|
230
Viatris
VTRS
$19.8B
| – | – |
-9,169
| Closed | -$172K |
|
|
QTNT
231
DELISTED
Quotient Limited Ordinary Shares
QTNT
| – | – |
-16,434
| Closed | -$3.42M |
|
|
CVET
232
DELISTED
Covetrus, Inc. Common Stock
CVET
| – | – |
-1,520
| Closed | -$44K |
|
|
CHNG
233
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| – | – |
-1,785,974
| Closed | -$33.3M |
|
|
XLNX
234
DELISTED
Xilinx Inc
XLNX
| – | – |
-4,200
| Closed | -$595K |
|
|
GNMK
235
DELISTED
GenMark Diagnostics, Inc
GNMK
| – | – |
-2,606,636
| Closed | -$38.1M |
|
|
OXFD
236
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| – | – |
-800,157
| Closed | -$14M |
|
|
BMY.RT
237
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| – | – |
-3,617,446
| Closed | -$2.5M |
|
Similar funds
WSFS
AC
HIP
DT
ATPW
BT
NCM
MSU
Bellevue Group's Q1 2021 Portfolio in Review
As of Q1 2021, Bellevue Group held 237 positions worth $9.45B, up 8.2% from $8.73B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Bellevue Group deployed $643M of net new capital in Q1 2021, opening 15 new positions and adding to 96 existing holdings. Its largest new stake was ESSA Pharma: 1,825,814 shares worth $53M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $86.9M trimmed.
- Bellevue Group's largest Q1 2021 buy was ESSA Pharma: 1,825,814 shares worth $53M.
- Bellevue Group added most to Accolade Inc in Q1 2021, an estimated $56.6M increase.
- Bellevue Group's biggest Q1 2021 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $86.9M.
- Bellevue Group fully exited GenMark Diagnostics, Inc in Q1 2021, selling an estimated $38.1M.
- Bellevue Group's ten largest holdings make up 29% of its $9.45B portfolio in Q1 2021.
- Bellevue Group opened 15 new positions and closed 21 in Q1 2021.
- Bellevue Group's portfolio value rose 8.2% quarter-over-quarter to $9.45B.
Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.